Cyrus J. Lawrence LLC Has $19.24 Million Position in Eli Lilly and Company (NYSE:LLY)

Cyrus J. Lawrence LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,251 shares of the company’s stock after selling 25 shares during the period. Eli Lilly and Company makes up 3.9% of Cyrus J. Lawrence LLC’s portfolio, making the stock its 5th biggest position. Cyrus J. Lawrence LLC’s holdings in Eli Lilly and Company were worth $19,240,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. AMJ Financial Wealth Management bought a new stake in Eli Lilly and Company in the 4th quarter worth approximately $201,000. Aveo Capital Partners LLC boosted its position in Eli Lilly and Company by 8.2% in the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after purchasing an additional 153 shares during the last quarter. Gryphon Financial Partners LLC grew its stake in shares of Eli Lilly and Company by 19.4% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after purchasing an additional 377 shares during the period. Quest Partners LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $313,000. Finally, Sepio Capital LP purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $291,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.7 %

LLY stock opened at $921.49 on Monday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The stock has a market capitalization of $875.79 billion, a price-to-earnings ratio of 135.71, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The firm’s fifty day simple moving average is $895.06 and its two-hundred day simple moving average is $838.73.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on LLY shares. Citigroup assumed coverage on Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price on the stock. Truist Financial reiterated a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $977.35.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 425,000 shares of company stock worth $394,455,351. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.